Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
Alexandra Pender,1 Robin L Jones1,2 1Sarcoma Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust, 2Division of Clinical Studies, The Institute of Cancer Research, London, UK Abstract: The outcome of patients with unresectable or metastatic soft tissue sarcoma (STS) remains poor with...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/61c57060328d44beabb0ff5b9876a106 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:61c57060328d44beabb0ff5b9876a106 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:61c57060328d44beabb0ff5b9876a1062021-12-02T01:54:29ZOlaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma1179-1438https://doaj.org/article/61c57060328d44beabb0ff5b9876a1062017-12-01T00:00:00Zhttps://www.dovepress.com/olaratumab-a-platelet-derived-growth-factor-receptor-alpha-blocking-an-peer-reviewed-article-CPAAhttps://doaj.org/toc/1179-1438Alexandra Pender,1 Robin L Jones1,2 1Sarcoma Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust, 2Division of Clinical Studies, The Institute of Cancer Research, London, UK Abstract: The outcome of patients with unresectable or metastatic soft tissue sarcoma (STS) remains poor with few treatment options. A number of randomized trials in the first-line setting have shown no difference in overall survival between combination anthracycline schedules and single-agent doxorubicin. A Phase Ib/randomized Phase II trial of doxorubicin with or without the platelet-derived growth factor receptor-α (PDGFRα)-blocking antibody, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm. The results of this trial led to the approval of olaratumab in combination with doxorubicin in adult anthracycline-naïve unresectable STS. In this review, we discuss the potential role of PDGFRα signaling, early clinical data with olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas. Keywords: olaratumab, sarcoma, PDGFRPender AJones RLDove Medical Pressarticleolaratumab sarcoma PDGFRTherapeutics. PharmacologyRM1-950ENClinical Pharmacology: Advances and Applications, Vol Volume 9, Pp 159-164 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
olaratumab sarcoma PDGFR Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
olaratumab sarcoma PDGFR Therapeutics. Pharmacology RM1-950 Pender A Jones RL Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma |
| description |
Alexandra Pender,1 Robin L Jones1,2 1Sarcoma Unit, Department of Medicine, The Royal Marsden NHS Foundation Trust, 2Division of Clinical Studies, The Institute of Cancer Research, London, UK Abstract: The outcome of patients with unresectable or metastatic soft tissue sarcoma (STS) remains poor with few treatment options. A number of randomized trials in the first-line setting have shown no difference in overall survival between combination anthracycline schedules and single-agent doxorubicin. A Phase Ib/randomized Phase II trial of doxorubicin with or without the platelet-derived growth factor receptor-α (PDGFRα)-blocking antibody, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm. The results of this trial led to the approval of olaratumab in combination with doxorubicin in adult anthracycline-naïve unresectable STS. In this review, we discuss the potential role of PDGFRα signaling, early clinical data with olaratumab in sarcomas, the Phase Ib/II trial and ongoing trials with olaratumab in sarcomas. Keywords: olaratumab, sarcoma, PDGFR |
| format |
article |
| author |
Pender A Jones RL |
| author_facet |
Pender A Jones RL |
| author_sort |
Pender A |
| title |
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma |
| title_short |
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma |
| title_full |
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma |
| title_fullStr |
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma |
| title_full_unstemmed |
Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma |
| title_sort |
olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma |
| publisher |
Dove Medical Press |
| publishDate |
2017 |
| url |
https://doaj.org/article/61c57060328d44beabb0ff5b9876a106 |
| work_keys_str_mv |
AT pendera olaratumabaplateletderivedgrowthfactorreceptoralphablockingantibodyforthetreatmentofsofttissuesarcoma AT jonesrl olaratumabaplateletderivedgrowthfactorreceptoralphablockingantibodyforthetreatmentofsofttissuesarcoma |
| _version_ |
1718402841731661824 |